The effect of orally administered Budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease A., Nowicki M., Kolodziejska-Sawerska A., Szweda M. (2017): The effect of orally administered Budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. Veterinarni Medicina, 62: 261-268.
download PDF
The aim of this study was to evaluate the effect of Budesonide on the hypothalamic-pituitary-adrenal (HPA) axis in dogs with inflammatory bowel disease. The effect of orally administered Budesonide (Entocort) on the HPA axis was analysed in 21 dogs with inflammatory bowel disease. Biochemical analyses were carried out to evaluate the activity levels of alanine aminotransferase, asparagine aminotransferase, alkaline phosphatase, cortisol and endogenous adrenocorticotropic hormone. Urine samples were collected from each patient before the study and after 30 days of the experiment to determine the composition and the physical and chemical properties of urine sediments. Considerably lower serum concentrations of cortisol and endogenous adrenocorticotropic hormone were observed after 30 days of treatment. A significant increase in alkaline phosphatase levels was noted on Day 30. In the studied dogs, the drop in HPA axis activity was correlated with side effects associated with the administered glucocorticosteroid (polyuria, polydipsia). In conclusion, we have shown that oral administration of Budesonide to dogs diagnosed with inflammatory bowel disease significantly suppressed the activity of the HPA axis.
Angelucci Erika, Malesci Alberto, Danese Silvio (2008): Budesonide: Teaching an Old Dog New Tricks for Inflammatory Bowel Disease Treatment. Current Medicinal Chemistry, 15, 2527-2535
Badylak SF, Van Vleet JF (1981): Sequential morphologic and clinicopathologic alterations in dogs with experimentally induced glucocorticoid hepatopathy. American Journal of Veterinary Research 42, 1310–1318.
Brattsand R (1990): Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel Disease. Canadian Journal of Gastroenterology, 4, 407-414
Brattsand Ralph, Miller-Larsson Anna (2003): The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clinical Therapeutics, 25, C28-C41
Campieri M, Ferguson A, Doe W, Persson T, Nilsson L-G, the Global Budesonide Study Group (1997): Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut, 41, 209-214
Craven M., Simpson J. W., Ridyard A. E., Chandler M. L. (2004): Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995-2002). Journal of Small Animal Practice, 45, 336-342
Day M.J., Bilzer T., Mansell J., Wilcock B., Hall E.J., Jergens A., Minami T., Willard M., Washabau R. (2008): Histopathological Standards for the Diagnosis of Gastrointestinal Inflammation in Endoscopic Biopsy Samples from the Dog and Cat: A Report from the World Small Animal Veterinary Association Gastrointestinal Standardization Group. Journal of Comparative Pathology, 138, S1-S43
DeNovo RC, Prasse KW (1983): Comparison of serum biochemical and hepatic functional alterations in dogs treated with corticosteroids and hepatic duct ligation. American Journal of Veterinary Research 44, 1703–1709.
Dillon AR, Sorjonen DC, Powers RD, Spano S (1983): Effects of dexamethasone and surgical hypotension on hepatic morphologic features and enzymes of dogs. American Journal of Veterinary Research 44, 1996–1999.
Dillon AR, Spano JS, Powers RD (1980): Prednisolone-induced hematologic, biochemical and histologic changes in the dog. Journal of the American Animal Hospital Association 16, 831–837.
Edsbacker S, Andersson T (2004): Pharmacokinetics of budesonide (EntocortEC) capsules for Crohn’s disease. Clinical Pharmacokinetics 43, 803–821.
Garcia-Sancho M., Rodríguez-Franco F., Sainz A., Mancho C., Rodríguez A. (2007): Evaluation of Clinical, Macroscopic, and Histopathologic Response to Treatment in Nonhypoproteinemic Dogs with Lymphocytic-Plasmacytic Enteritis. Journal of Veterinary Internal Medicine, 21, 11-17
Greenberg Gordon R., Feagan Brian G., Martin Francois, Sutherland Lloyd R., Thomson Alan, Williams C. Noel, Nilsson Lars-Goran, Persson Tore (1994): Oral Budesonide for Active Crohn's Disease. New England Journal of Medicine, 331, 836-841
Jergens AE, Simpson KW (2012): Inflammatory bowel disease in veterinary medicine. Frontiers in Bioscience (Elite Edition) 4, 1404–1419.
Jergens Albert E., Schreiner C. Alan, Frank Dagmar E., Niyo Yosiya, Ahrens Franklin E., Eckersall P.D., Benson Tammy J., Evans Richard (2003): A Scoring Index for Disease Activity in Canine Inflammatory Bowel Disease. Journal of Veterinary Internal Medicine, 17, 291-297
Jonsson G, Astrom A, Andersson P (1995): Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metabolism and Disposition 23, 137–142.
Lundin P. D. P., Edsbacker S., Bergstrand M., Ejderhamn J., Linander H., Hogberg L., Persson T., Escher J. C., Lindquist B. (2003): Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Alimentary Pharmacology and Therapeutics, 17, 85-92
Malewska K., Rychlik A., Nieradka R., Kander M. (2011): Treatment of inflammatory bowel disease (IBD) in dogs and cats. Polish Journal of Veterinary Sciences, 14, -
Meyer DJ (1982): Prolonged liver test abnormalities and adrenocortical suppression in a dog following a single intramuscular glucocorticoid dose. Journal of the American Animal Hospital Association 18, 725–727.
Meyer DJ, Moriello KA, Feder BM, Fehrer-Sawyer SL, Maxwell AK (1990): Effect of otic medications containing glucocorticoids on liver function test results in healthy dogs. Journal of the American Veterinary Medical Association 196, 743–744.
Miller-Larsson A., Gustafsson B., Persson C. G. A., Brattsand R. (2001): Gut mucosal uptake and retention characteristics contribute to the high intestinal selectivity of budesonide compared with prednisolone in the rat. Alimentary Pharmacology and Therapeutics, 15, 2019-2025
Raff H (1987): Glucocorticoid inhibition of neurohypophysial vasopressin secretion. American Journal of Physiology 252, 635–644.
Rutgers HC, Batt RM, Vaillant C, Riley JE (1995): Subcellular pathologic features of glucocorticoid-induced hepatopathy in dogs. American Journal of Veterinary Research 56, 898–907.
Schlaghecke Reiner, Kornely Elisabeth, Santen Reinhard Th., Ridderskamp Paul (1992): The Effect of Long-Term Glucocorticoid Therapy on Pituitary–Adrenal Responses to Exogenous Corticotropin-Releasing Hormone. New England Journal of Medicine, 326, 226-230
Simpson KW, Jergens AE (2011): Pitfalls and progress in the diagnosis and management of canine inflammatory bowel disease. Veterinary Clinics: Small Animal Practice 41, 381–398.
Spencer CM, McTavish D (1995): Budesonide: a review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 50, 854–872.
Stroup Shannon T., Behrend Ellen N., Kemppainen Robert J., Smith-Carr Saralyn (2006): Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. American Journal of Veterinary Research, 67, 1173-1178
Thomsen Ole Østergaard, Cortot Antoine, Jewell Derek, Wright John P., Winter Trevor, Veloso Fernando Tavarela, Vatn Morten, Persson Tore, Pettersson Eva (1998): A Comparison of Budesonide and Mesalamine for Active Crohn's Disease. New England Journal of Medicine, 339, 370-374
Tumulty Joshua W., Broussard John D., Steiner Jörg M., Peterson Mark E., Williams David A. (2004): Clinical Effects of Short-Term Oral Budesonide on the Hypothalamic-Pituitary-Adrenal Axis in Dogs With Inflammatory Bowel Disease. Journal of the American Animal Hospital Association, 40, 120-123
Washabau RJ (2008): Summary of findings and reports of the WSAVA Gastrointestinal Standardization Group. The 33rd WSAVA Congress, Dublin. August 20–24, 2008. 60–62.
Zareie M, Brattsand R, Sherman PM, McKay DM, Perdue MH (1999): Improved effects of novel glucocorticosteroids on immune-induced epithelial pathophysiology. Journal of Pharmacology and Experimental Therapeutics 289, 1245–1249.
download PDF

© 2022 Czech Academy of Agricultural Sciences | Prohlášení o přístupnosti